Thermo Fisher acquires Novasep's viral vector manufacturing business
Adding Henogen S.A. furthers its efforts in cell and gene-based therapy development
Thermo Fisher Scientific Inc. and Groupe Novasep SAS, a services and technologies supplier for the life sciences industry, announced that Thermo Fisher has acquired Henogen S.A., Novasep’s viral vector manufacturing business in Belgium, for approximately €725 million (about $876 million) in cash.
Henogen S.A. will be part of Thermo Fisher's pharma services business within the laboratory products and services segment.
Between its two locations in Seneffe and Gosselies, Belgium, the business offers contract manufacturing services for both vaccines and therapies to biotech companies and large biopharma customers via approximately 75,347 square feet of capacity. The business' estimated 2020 revenue was €80 million (approximately $97 million).
Thermo Fisher previously announced plans to construct a 67,000-sq.-ft. plasmid DNA manufacturing facility in Carlsbad, CA last month.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
